Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00693212 · ClinicalTrials.gov registry record · Phase 3
Further Studies of Attention Deficit Disorder - Residual Type (RT)
A Phase 3 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 3
- Development phase
- 116
- Enrollment target
NCT00693212: Completed Phase 3 study, sponsored by University of Utah.
NCT00693212 is a Phase 3 study that has completed, run by University of Utah. The registered enrollment target is 116 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00693212, a Phase 3 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 116 participants
- Enrollment target
Study Summary
The first phase was a double-blind crossover design of methylphenidate in the treatment of adult ADHD. The second phase consisted of an open-label extension trial of methylphenidate in adult ADHD. It was hypothesized that methylphenidate would prove more effective than placebo in treating ADHD symptoms during the first phase. It was also hypothesized that methylphenidate responders from the double-blind trial would continue to benefit from treatment in the second phase. Improvement would include both ADHD symptoms and social adjustment.
Interventions
- DRUG placebo
- DRUG methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 1986-02 |
| Est. Completion | 1994-11 |
| Phase | Phase 3 |
What the finished NCT00693212 record still lists
NCT00693212 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00693212 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00693212 about?
NCT00693212 is a clinical study titled "Further Studies of Attention Deficit Disorder - Residual Type (RT)". The first phase was a double-blind crossover design of methylphenidate in the treatment of adult ADHD. The second phase consisted of an open-label extension trial of methylphenidate in adult ADHD. It was hypothesized that methylphenidate would prove more effective than placebo in treating ADHD sympt...
What is the current status of trial NCT00693212?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 116 participants. The study started on 1986-02. Estimated completion is 1994-11.
What interventions are being tested in trial NCT00693212?
The interventions under investigation include: placebo (DRUG), methylphenidate (DRUG).
Who is sponsoring clinical trial NCT00693212?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00693212's enrollment target sits among peer trials
116 1643rd of 2000 higher than 357 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia